Through analysis of IO clinical trials (2018–2022), we reveal how top‑20 pharma concentrate on mAb trials globally, while smaller firms explore innovative modalities like BsAb and CAR‑T, and how China is emerging as an IO hub. These patterns offer strategic cues for reshaping your trial portfolio and R&D focus.
Strategic Considerations for a World in Flux
Before COVID-19 transpired executives were concerned with their strategic assumptions and the results of getting them wrong. A February 2020 Gartner study cited lack of confidence in strategic assumptions as the leading corporate risk among senior executives across a diverse set of industries and global geographies in Q4 2019. A strategic assumption can be defined as the unstated belief that something is likely to occur to enable an achievable strategic goal. Depending on the …
Six Degrees of Connection
Improve the ROI and sustainability of competitive intelligence in your organization by linking CI to Strategy using six analytical tools. In order to increase the ROI, and thus the sustainability, of Competitive Intelligence (CI) within your organization, it is essential to link research with strategy. While there is a growing dialogue concerning the need to increase the impact of CI …